Read all about what is happening with CSRO. To view our Bi-Weekly Updates, click here. To view the latest editions of Rheum for Action, click here.
Reform is needed to protect patients
The Gazette | April 12, 2025
Read Now ⇒
Healthcare in Crisis: The Truth About PBMs with Dr. Madelaine Feldman
HOPE Podcast | April 7, 2025
Watch Now ⇒
PBM Private Labeling Boosts Biosimilar Adoption, Raises Anticompetitive Concerns
Medscape | April 3, 2025
Read Now ⇒
When a Drug Discount Program Becomes a Hospital Profit Engine, Patients Lose
The Gilmer Mirror | April 3, 2025
Read Now ⇒
Opinion: Tennessee lawmakers should finish 2021 work to protect patients from middlemen preying on medication assistance for vulnerable Tennesseans
Chattanooga Times Free Press | March 24, 2025
Read Now ⇒
Column: Governor, veto the prescription drug board bill
The Virginian-Pilot | March 17, 2025
Read Now ⇒
The Most Common Questions I Get Asked By Young Doctors
WCI | March 14, 2025
Read Now ⇒
Governor Youngkin should veto Prescription Drug Affordability Boards, again
Cardinal News | March 11, 2025
Read Now ⇒
FTC report on pharmacy benefit managers uncovers a system ‘addicted to higher list prices’
Healio | March 7, 2025
Read Now ⇒
Medicare pay cuts: How they threaten patients’ access to care
AMA | March 6, 2025
Read Now ⇒
CSRO Winter 2025 Policy Update
CSRO | February 14, 2025
View Now ⇒
Lawmakers must support doctors, patients
The Daily Record | January 9, 2025
Read Now ⇒
To protect Virginia clinics and patients, improve federal safety net program accountability
December 12, 2024
Read Now ⇒
Independently Owned Kansas Pharmacies Struggle to Stay Open
September 29, 2024
Read Now ⇒
Opinion: Prior Authorization Remains a Barrier to Patient Care
September 18, 2024
Read Now ⇒
FTC Interim Report Shows Need for Action on Pharmacy Middlemen: Q&A
August 14, 2024
Read Now ⇒
Alternative PBMs Arise to Compete With the 'Big Three'
August 7, 2024
Read Now ⇒
Seen the Headlines? It’s Time for PBM Reform
July 23, 2024
CSRO joined the Community Oncology Alliance (COA), The Food Industry Association (FMI), the National Association of Chain Drug Stores (NACDS), and the National Community Pharmacists Association (NCPA) in sponsoring an ad that went into the Wall Street Journal to coincide with the PBM executives testifying before the House Committee on Oversight and Accountability hearing on July 23.
View Ad ⇒
CSRO Explanatory Statement: “Underwater” Biosimilars
May 14, 2024
CSRO continues to receive reports from practices nationwide about the financial challenges posed by certain biosimilars for which acquisition costs exceed reimbursement levels. This problem was first noted with Inflectra® (infliximab-dyyb), a biosimilar for Remicade®, but has now extended to Avsola® (infliximab-axxq), another Remicade® biosimilar, as well as several Rituxan® (rituximab)biosimilars.
Read Now ⇒
Understanding the pitfalls of AFPs
May 2, 2024
Read Now ⇒
Affordable Rural Medication Program Is Rife With Abuse. Missouri, Don’t Make It Worse
April 23, 2024
Read Now ⇒
Dr. Harry Gewanter Explains Why PDABs Hurt Patients’ Access to Medicines
April 3, 2024
Read Now ⇒
Letter: Mississippi's misguided health care proposal
April 2, 2024
Read Now ⇒
Opinion: Gov. Youngkin, please veto the Prescription Drug Affordability Board legislation
April 1, 2024
Read Now ⇒
Alternative Funding Programs: What Employers Need to Know
February 20, 2024
Read Now ⇒
CSRO Policy Update: Winter 2024
February 20, 2024
Read Now ⇒
Congress Can Fix the Broken PBM Industry
February 14, 2024
Read Now ⇒
Health Care Antitrust Weekly: Vol. 12 No. 42
January 24, 2024
Read Now ⇒
Letters: Step therapy rules need reform so patients can access treatment
January 9, 2024
Read Now ⇒
Addressing the real culprits of rising drug prices | Opinion
January 7, 2024
Read Now ⇒
FDA Approves Florida's Proposal to Import Prescription Drugs From Canada
January 5, 2024
Read Now ⇒
Final 2024 Medicare PFS Boosts Rheumatology Pool by 2%
November 10, 2023
Read Now ⇒
Underwater with Biosimilars: What You Should Know
September 27, 2023
CSRO continues to hear from practices around the country about biosimilars being “underwater” in terms of acquisition cost versus reimbursement level. Although this issue first emerged with regard to Inflectra, it seems to exist for other biosimilars now as well.
Read Now ⇒
CSRO 2023 State Society Advocacy Conference: In Review
September 1, 2023
Read Now ⇒
Reform of ‘Insurance middlemen’ is overdue for NC families
August 3, 2023
Read Now ⇒
CSRO Policy Update: Summer 2023
August 3, 2023
Read Now ⇒
The ‘great American switching experiment’: Cyltezo debut ushers in interchangeable era
July 24, 2023
Read Now ⇒
Proposal to Cap Part B Pay on Some Drugs Draws Opposition
June 20, 2023
Read Now ⇒
Opinion: Health insurance too often fails to make the grade
June 15, 2023
Read Now ⇒
Permission to Prescribe: Physicians allege insurance intermediaries, red tape are driving decisions about care, with patients paying the price
June 12, 2023
Read Now ⇒
Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts
June 1, 2023
Read Now ⇒
Letters: Government must address equity in health care
May 2, 2023
Read Now ⇒
Bipartisan Senate Plan Would Regulate PBM Compensation, Target ‘Unfair’ Drug Price Hikes
April 24, 2023
Read Now ⇒
Rheumatology Fellows Learn About Career Opportunities
March 17, 2023
Read Now ⇒
New Rheumatologists Need Insurance Awareness to Give Best Care
March 17, 2023
Read Now ⇒
CSRO Policy Update: Winter 2023
February 10, 2023
Read Now ⇒
Amgen’s acquisition of Horizon could have ‘downstream effects’ in rheumatology
February 2, 2023
Read Now ⇒
Iowa health plans don’t provide stable care for chronic illness
January 29, 2023
Read Now ⇒
Looking for an older article? Email CSRO at info@csro.info to review our news archive.
